<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Germany</title>
	<atom:link href="http://www.tapanray.in/tag/germany/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Astronomical Prices of Patented Cancer Drugs: A Solution in Sight?</title>
		<link>http://www.tapanray.in/astronomical-prices-of-patented-cancer-drugs-a-solution-in-sight/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=astronomical-prices-of-patented-cancer-drugs-a-solution-in-sight</link>
		<comments>http://www.tapanray.in/astronomical-prices-of-patented-cancer-drugs-a-solution-in-sight/#comments</comments>
		<pubDate>Thu, 20 Feb 2014 13:25:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[astronomical]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Dasatinib]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Germany]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interministerial]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pharmaco-economics]]></category>
		<category><![CDATA[PHFI]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reserachers]]></category>
		<category><![CDATA[sight]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5014</guid>
		<description><![CDATA[Astronomical prices of patented anti-cancer dugs have become a subject of great concern not just in India. It is becoming an issue across the world. After issuing the first ever Compulsory License (CL) for Nexavar of Bayer in India, the &#8230; <a href="http://www.tapanray.in/astronomical-prices-of-patented-cancer-drugs-a-solution-in-sight/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/astronomical-prices-of-patented-cancer-drugs-a-solution-in-sight/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pioglitazone Conundrum: Should The Drug Regulator Step Over The Line?</title>
		<link>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line</link>
		<comments>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/#comments</comments>
		<pubDate>Mon, 08 Jul 2013 00:00:54 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Actos]]></category>
		<category><![CDATA[Agency]]></category>
		<category><![CDATA[assembly]]></category>
		<category><![CDATA[Australia]]></category>
		<category><![CDATA[bladder]]></category>
		<category><![CDATA[canadian]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[claim]]></category>
		<category><![CDATA[combinations]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[cosmetics]]></category>
		<category><![CDATA[diabetics]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[flutter]]></category>
		<category><![CDATA[France]]></category>
		<category><![CDATA[French]]></category>
		<category><![CDATA[general]]></category>
		<category><![CDATA[Germany]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[increased]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[indudtry]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[intriguing]]></category>
		<category><![CDATA[Japan]]></category>
		<category><![CDATA[JAPI]]></category>
		<category><![CDATA[liability]]></category>
		<category><![CDATA[line]]></category>
		<category><![CDATA[List]]></category>
		<category><![CDATA[manufacturers]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[nations]]></category>
		<category><![CDATA[over]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pharmacovigilance]]></category>
		<category><![CDATA[Pioglitazone]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Profile]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[ruffling]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Section 26A]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[Sweden]]></category>
		<category><![CDATA[Takeda]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[UN]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[withdrawal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2883</guid>
		<description><![CDATA[Recent order of the Indian drug regulator to withdraw all formulations of the well known, yet controversial, anti-diabetic drug &#8211; Pioglitazone from the domestic market has created a flutter in the country, ruffling many feathers at the same time. Withdrawal &#8230; <a href="http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>In the Wonderland of Pharma Generics: Some Steps In, Some Steps Over the Line</title>
		<link>http://www.tapanray.in/in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line</link>
		<comments>http://www.tapanray.in/in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line/#comments</comments>
		<pubDate>Mon, 10 Jun 2013 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[allegations]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[blockbusters]]></category>
		<category><![CDATA[blocking]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[disparaging]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[entering]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Germany]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HLEG]]></category>
		<category><![CDATA[Holland]]></category>
		<category><![CDATA[Impax]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[intriguing]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[NUT]]></category>
		<category><![CDATA[Opana]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[OxyContin]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[Purdue]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sankyo]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[TevaSante]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[ZydusCadila]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2234</guid>
		<description><![CDATA[To scale-up access to healthcare, especially for the marginalized population of any country, greater access to affordable generic drugs will always remain fundamental, besides improving healthcare infrastructure and its delivery mechanism. Thus, there should be a robust mechanism across the &#8230; <a href="http://www.tapanray.in/in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
